Jump to content

Drilldown: Medicines

Pharmacopedia
BrowseCategoriesLog in

Choose a table:


Medicines > classes : Anti-amyloid beta (Aβ) monoclonal antibody or Tryptamine & halflife: ~5-7 days

Use the filters below to narrow your results.

generic:
None (1)
brand:
Leqembi (1)
classes: (Click arrow to add another value)
mechanism:
None (1)
uses:
Alzheimer disease (MCI or mild dementia stage); FDA accelerated approval Jan 2023 → traditional approval July 2023 (1)
starting dose:
10 mg/kg IV every 2 weeks (1)
preparations:
200 mg/2 mL, 500 mg/5 mL vials for IV infusion (1)
fda max:
10 mg/kg q2w (1)
routes:
IV infusion (60 min) every 2 weeks; outpatient or infusion-center setting (1)
onset:
Slowing of cognitive decline over 18 months (modest effect, ~27% relative slowing) (1)
duration:
Ongoing dosing (1)
halflife: (Click arrow to add another value)
bioavailability:
100% (IV) (1)
pregnancy:
Limited data (1)
legal:
Rx; REMS-like program for ARIA monitoring (1)

Showing below up to 1 result in range #1 to #1.

View (previous 250 | next 250) (20 | 50 | 100 | 250 | 500)


View (previous 250 | next 250) (20 | 50 | 100 | 250 | 500)

Retrieved from "https://pharmacopedia.wiki/p/Special:Drilldown/Medicines"